The worldwide oncology market is projected to outgrow the rest of the...

The prostate cancer market is reaching maturity, and major players' sales have been eroded by...

However the company issued disappointing 2010 earnings-per-share guidance of $5.75 to $6.15, which is slightly below our projections.

Based on the company's outlook, we will likely...

28 (Bloomberg) -- AstraZeneca Plc fell the most in more than 10 months in London trading after the U.K.

drugmakers sales forecast and stock buyback disappointed some analysts and fourth-quarter profit...

The agency won the brief following a two-way shoot-out against Cohn & Wolfe.

Industry sources suggested the account could be worth up to 500,000....

Introduction Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer.

The high incidence of these tumor types translates...